Towards the Optimisation of the Production of Monoclonal Antibodies

Abstract A systematic research strategy is proposed for the control and optimisation of monoclonal antibody (MAb) production from mammalian cell cultures. This approach consists of a novel model-based methodology for the design of dynamic experiments to minimise the required experimentation and to improve parameter precision, as well as model-based control and optimisation techniques. This framework is to be applied to a novel integrated, unstructured, dynamic model, which incorporates growth kinetics, cell death, cell metabolism, cell cycle, and MAb synthesis, glycosylation, and production; the simulation results of which demonstrate its satisfactory predictive capability. For the purpose of unique parameter estimation, global sensitivity analysis is performed on the proposed model, through which the parameters with significant impact on the model output, i.e. MAb concentration, are identified

[1]  M. Al‐Rubeai,et al.  Cell death in bioreactors: A role for apoptosis , 1994, Biotechnology and bioengineering.

[2]  J. Ljunggren,et al.  Physiology of cultured animal cells. , 1997, Journal of biotechnology.

[3]  I. Sobola,et al.  Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates , 2001 .

[4]  John P. Barford,et al.  An unstructured kinetic model of macromolecular metabolism in batch and fed-batch cultures of hybridoma cells producing monoclonal antibody , 2000 .

[5]  Steven P. Asprey,et al.  Parametric identifiability of a structured kinetic model for mammalian cell cultures , 2003 .

[6]  J E Bailey,et al.  A mathematical model of N-linked glycoform biosynthesis. , 1997, Biotechnology and bioengineering.

[7]  S Shioya,et al.  Modeling and optimization of alpha-amylase production in a recombinant yeast fed-batch culture taking account of the cell cycle population distribution. , 1999, Journal of biotechnology.

[8]  M. Flickinger,et al.  Use of a structured kinetic model of antibody synthesis and secretion for optimization of antibody production systems: I. Steady‐state analysis , 1992, Biotechnology and bioengineering.

[9]  S. Chamow,et al.  Therapeutic antibody expression technology. , 2001, Current opinion in biotechnology.

[10]  Steven P. Asprey,et al.  Global Parametric Identifiability of a Dynamic Unstructured Model of Hybridoma Cell Culture , 2001 .

[11]  M. Soroush,et al.  Multi‐rate nonlinear state and parameter estimation in a bioreactor , 1999 .